ProQR Therapeutics (PRQR) Enterprise Value (2012 - 2026)
ProQR Therapeutics (PRQR) posted Enterprise Value of -$94.9 million for Q1 2026, up 11.74% sequentially from -$107.6 million in Q4 2025, and up 31.83% YoY from -$72.0 million in Q1 2025.
ProQR Therapeutics (PRQR) Enterprise Value (2012 - 2026) Analysis & Trends
ProQR Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$94.9 million in Q1 2026.
- Quarterly Enterprise Value rose 31.83% year-over-year to -$94.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.9 million (up 31.83% YoY) and the FY2025 annual result came in at -$107.6 million, up 32.62% from the prior year.
- Enterprise Value climbed to -$94.9 million in Q1 2026 per PRQR's latest filing, from -$107.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$94.9 million in Q1 2026 and troughed at -$188.8 million in Q1 2022.
- A 5-year average of -$128.2 million and a median of -$128.0 million in 2023 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 54.89% in 2022, down 130.59% in 2022.
- Over 5 years, Enterprise Value stood at -$97.1 million in 2022, then plunged by 31.8% to -$128.0 million in 2023, then declined by 24.77% to -$159.7 million in 2024, then jumped by 32.62% to -$107.6 million in 2025, then rose by 11.74% to -$94.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$94.9 million, -$107.6 million, and -$125.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | -94.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -94.95 Mn |
| Dec 31, 2025 | -107.57 Mn |
| Sep 30, 2025 | -124.95 Mn |
| Jun 30, 2025 | -135.57 Mn |
| Mar 31, 2025 | -139.28 Mn |
| Dec 31, 2024 | -159.66 Mn |
| Sep 30, 2024 | -98.18 Mn |
| Jun 30, 2024 | -103.55 Mn |
| Mar 31, 2024 | -111.58 Mn |
| Dec 31, 2023 | -127.96 Mn |
| Sep 30, 2023 | -131.23 Mn |
| Jun 30, 2023 | -140.31 Mn |
| Mar 31, 2023 | -149.51 Mn |
| Dec 31, 2022 | -97.09 Mn |
| Sep 30, 2022 | -101.65 Mn |
| Jun 30, 2022 | -167.31 Mn |
| Mar 31, 2022 | -188.80 Mn |
| Dec 31, 2021 | -215.21 Mn |
| Sep 30, 2021 | -184.82 Mn |
| Jun 30, 2021 | -168.60 Mn |